Motley Fool

Could This Be Pfizer’s Next Blockbuster Vaccine?

Pfizer (NYSE: PFE) was arguably a prolific vaccine maker before last month, when the U.S. Food and Drug Administration gave full approval for those 16 and older to its COVID-19 vaccine, Comirnaty, which it co-developed with BioNTech (NASDAQ: BNTX). After all, Pfizer owns the Prevnar pneumococcal vaccine franchise, which brought in $2.52 billion in revenue during the first half of this year. Pfizer’s tick-borne encephalitis vaccine, known as TicoVac, also secured FDA approval in the U.S. last month, which could multiply its revenue several times over to about $1 billion annually.

LEAVE A REPLY

Please enter your comment!
Please enter your name here